Loading…

Novartis AGNOVN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Pharmaceuticals: Major

Swiss pharmaceutical company developing and selling prescription medicines across oncology, cardiovascular, immunology, and neuroscience.

≈ A Swiss Merck & Co / Bristol-Myers Squibb hybridMomentum strong 60
Mkt cap
$285B
US dollars, full cap
Free float
88%
of shares outstanding
$/day
$541M
20-day average traded
Fwd P/E
17.5×
forward earnings
ROIC−WACC
+11.8 pp
WACC 5.0%
Hurdle
+2 pp
Req g minus delivered
Official | Implied
AA- / AAA
agencies · bond market
Next earnings
77 days
3 Feb 2027
Close · CHFCHF 131.48
1D-1.4%
1W-0.9%
1M+3.9%
3M+3.2%
6M+11.0%
YTD+20.0%
1Y+25.9%
ATR %1.9%
52w lowhigh4.0% off high

What Novartis does

Swiss pharmaceutical company developing and selling prescription medicines across oncology, cardiovascular, immunology, and neuroscience.

Earns by selling patented medicines through hospitals and health systems, with a handful of top-selling brands carrying the business. It is now a pure prescription-medicines company after spinning off Alcon, the eye-care business, in 2019 and Sandoz, the generics business, in 2023.

In one line: A Swiss Merck & Co / Bristol-Myers Squibb hybrid.

Products and services

  • Oncology drugs
  • Cardiovascular/renal drugs
  • Immunology drugs
  • Ophthalmology (former Alcon, now spun off)

Customers

  • Hospitals and specialist prescribers
  • Patients via healthcare systems

Where it sits in the supply chain

  • Healthcare
  • Pharmaceuticals
  • Drug discovery, development, and…

What could go right

  • New drug launches/pipeline maturation
  • Radioligand therapy platform growth

What could go wrong

  • Patent expirations/generic competition
  • Drug pricing policy risk

Moat: wide (IP / patents, scale, regulatory licence). Broad patent-protected drug portfolio across major therapeutic areas built on decades of R&D scale.

Headquarters: Basel, Switzerland · Founded: 1996 · Employees: 75,267

Named competitors

Novartis at a glance

Size Novartis (NOVN.SW) is a Switzerland Health Care company (Pharmaceuticals: Major) with a market value of $285B, the 2nd largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 131.48 on 18 Nov 2026.

Performance Over six months the shares gained 11.0%, against +13.0% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 7th lowest of 14 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median +5.7%); the operating margin is 30.5% (peer median 30.4%).

Valuation It trades at 17.5× forward earnings against a peer median of 16.4× (7th most expensive of 14).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 11.8 points above its cost of capital (5.0% WACC).

Credit Novartis has 8 bonds outstanding ($6.82B), rated AA- by the agencies and trading like AAA at a weighted spread of 49 bp.

Next results Next results expected around 3 Feb 2027 (exchange calendar; dates can move).

Relative performance

10011012021 May 202621 Aug 202618 Nov 2026Peer median 112NOVN.SW 110
Six months, rebased to 100: Novartis against the median of its 13 peers (local-currency closes).

Novartis financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCHF 44.1BCHF 45.3BCHF 44.3BCHF 40.8BCHF 40.3B
Revenue growth—+2%+9%+1%—
Gross profitCHF 32.8BCHF 34.0BCHF 33.0BCHF 29.5BCHF 29.4B
EBITDACHF 17.6BCHF 18.5BCHF 18.9BCHF 18.1BCHF 16.3B
Net incomeCHF 7.95BCHF 11.6BCHF 10.5BCHF 13.3BCHF 6.64B
Free cash flowCHF 12.3BCHF 14.6BCHF 14.3BCHF 12.0BCHF 12.7B
Capital expenditureCHF 2.65BCHF 3.24BCHF 3.36BCHF 2.47BCHF 2.14B
Total debtCHF 40.3BCHF 28.0BCHF 28.3BCHF 22.2BCHF 25.8B

Quarterly statements and history in the cockpit →

Novartis competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%AZNMRKRONOVO-BABBVPFEVRTXBMYSANGSKREGN4519NOVN.SW6-month return →1-month return →
Up and to the right = strong over both horizons. Novartis is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%10×20×30×AZNMRKRONOVO-BABBVPFEVRTXJNJBMYSANGSKREGN4519NOVN.SWRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Novartis is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%-10%0%10%20%AZNMRKRONOVO-BABBVPFEVRTXJNJBMYSANGSKREGN4519NOVN.SWGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Novartis is the large dot.

Novartis competitors and peer comparison

Head to head with its named competitors (NOVN.SW vs RO.SW vs PFE vs MRK)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
Roche RO.SW$381B+21%-1%31%19.9×1.7%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Merck & MRK$340B+23%+5%18%16.4×8.3%
AstraZeneca AZN.L$278B-2%+5%23%17.6×14.4%

How Novartis compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Novartis against its 13 peers (data as of 18 Nov 2026)
MeasureNOVN.SWPeer medianRank in peer set
1-month return+3.9%+3.9%7th highest of 14
6-month return+11.0%+13.0%7th lowest of 14
Distance from 52-week high-4.0%-10.8%3rd highest of 14
Revenue growth (TTM)-4.5%+5.7%lowest of 14
Operating margin30.5%30.4%7th highest of 14
Forward P/E17.5×16.4×7th most expensive of 14
Growth the price implies (Req g, 7 yrs)1.6%-0.1%7th most demanding of 14
Growth delivered (Del g)-0.2%+8.5%2nd lowest of 14
Hurdle (Req g minus delivered)+1.7 pp-6.0 ppmost demanding of 14
ROIC minus cost of capital+11.8 pp+10.5 pp7th highest of 14
EV / EBITDA15.5×14.9×7th most expensive of 14
Net debt / EBITDA1.9×1.0×5th most indebted of 14
Bond spread49 bp68 bp3rd tightest of 12

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Merck & MRKUnited States$340B+23%+5%18%16.4×8.3%+9.3%
Roche RO.SWSwitzerland$381B+21%-1%31%19.9×1.7%+1.1%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
AbbVie ABBVUnited States$506B+35%+11%36%18.1×-0.1%+6.0%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Johnson & Johnson JNJUnited States$656B+20%+8%26%24.2×3.7%+2.7%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%

Novartis bonds and credit

Novartis has 8 bonds outstanding with $6.82B face value. The agencies rate it AA-; its bonds trade like AAA. Weighted yield 3.73%, a spread of 49 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Novartis's main competitors?
Named competitors: Roche (RO.SW), Pfizer (PFE), Merck & Co (MRK), AstraZeneca (AZN.L). The cockpit's measured peer set (industry) also includes AstraZeneca (AZN.L), Merck & (MRK), Roche (RO.SW), Novo Nordisk A/S (NOVO-B.CO), AbbVie (ABBV), Pfizer (PFE).
Is Novartis expensive compared with its peers?
On forward p/e it trades at 17.5× against a peer median of 16.4×, 7th most expensive of 14 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is 0%, so the hurdle is +2 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Novartis stock performed?
Over six months to 18 Nov 2026 the shares returned +11.0% against +13.0% for the median peer; over one year +25.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.